ADVFN - Advanced Financial Network.
HOME» NASDAQ » M » MYL Stock Price » MYL Stock News

Mylan Inc. Share News

 Mylan Inc. (mm) Stock Price
MYL Stock Price
 Mylan Inc. (mm) Stock Chart
MYL Stock Chart
 Mylan Inc. (mm) Stock News
MYL Stock News
 Mylan Inc. (mm) Company Information
MYL Company Information
 Mylan Inc. (mm) Stock Trades
MYL Stock Trades

US Judge Upholds Validity Of Merck's Vytorin Patent

By Peter Loftus Of DOW JONES NEWSWIRES A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (MRK) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years. In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable. Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017. Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable. Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday. On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said. A Mylan spokeswoman couldn't immediately be reached. Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million. Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581;

Stock News for Mylan Inc. (MYL)
09/26/201620:10:00Mylan's EpiPen Pretax Profits 60% Higher Than Number Told to...
09/26/201612:09:56Current Report Filing (8-k)
09/26/201611:50:00Mylan Clarifies EpiPen Profit Figures it Provided to Congress...
09/21/201610:50:00Mylan CEO to Shift Blame on EpiPen Pricing at Hearing
09/14/201623:20:00EpiPen Maker Executive to Testify at House Hearing
09/11/201623:20:00Starboard Value Takes 4.6% Stake in Perrigo
09/06/201617:23:20Amended Current Report Filing (8-k/a)
09/06/201617:23:14Current Report Filing (8-k)
09/01/201615:12:00Mylan Invalidates Third Teva Copaxone® 40 mg/mL Patent Via U.S...
09/01/201608:20:00EpiPen Maker Mylan Tied Pay to Aggressive Profit Targets
08/29/201608:10:00Mylan, Feeling Heat on EpiPen Price, Will Offer Cheaper Generic
08/29/201606:00:00Mylan to Launch First Generic to EpiPen® Auto-Injector at a...
08/25/201609:45:00U.S. Hot Stocks: Hot Stocks to Watch
08/25/201608:30:00Mylan Boosts Price Assistance for EpiPen Amid Backlash
08/25/201607:00:00Mylan Taking Immediate Action to Further Enhance Access to EpiPen®...
08/25/201606:30:00Mylan and Biocon Announce Regulatory Submission for Proposed...
08/24/201618:20:00Mylan Faces Scrutiny Over EpiPen Price Increases
08/24/201616:47:00Mylan Invalidates Two of Teva's Copaxone® 40 mg/mL Patents Via...
08/11/201619:02:12Statement of Changes in Beneficial Ownership (4)
08/11/201617:17:24Current Report Filing (8-k)

Mylan Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations